Company profile: Calliditas Therapeutics
1.1 - Company Overview
Company description
- Provider of specialty pharmaceuticals for unmet medical needs in niche indications, including TARPEYO (delayed-release budesonide for renal diseases), Kinpeygo (renal and hepatic diseases), NEFECON (candidate for primary IgA nephropathy), and Setanaxib (NOX1/4 inhibitor in trials for PBC and head & neck cancer), plus pipeline development for orphan renal/hepatic diseases and strategic partnerships for development and commercialization.
Products and services
- TARPEYO: A delayed-release capsule of budesonide engineered to treat renal diseases, leveraging timed drug delivery for targeted therapeutic impact in kidney-related indications
- Setanaxib: A first-in-class NOX1/4 inhibitor advancing in Phase 2b/3 PBC and Phase 2 head and neck cancer studies, evidencing dual-indication clinical development
- NEFECON: A clinical-stage drug candidate aimed at treating primary IgA nephropathy, currently in trial phase, developed to address significant unmet medical need in this renal indication
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Calliditas Therapeutics
Enobia Pharma
HQ: Canada
Website
- Description: Provider of therapies for serious genetic bone disorders, focused on conditions with no approved treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enobia Pharma company profile →
Akarna Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of novel small molecule therapeutics targeting inflammatory and fibrotic diseases, including a non-bile acid FXR agonist for nonalcoholic steatohepatitis (NASH), aiming to deliver best-in-class treatments for chronic liver diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akarna Therapeutics company profile →
QOL Medical
HQ: United States
Website
- Description: Provider of specialty biopharmaceutical products and services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QOL Medical company profile →
Aligos Therapeutics
HQ: United States
Website
- Description: Provider of small molecule and oligonucleotide platforms and a pipeline of drug candidates for MASH and viral diseases, including COVID-19 protease inhibitors (partly funded by NIH and NIAID), a capsid assembly modulator (ALG-000184) for chronic hepatitis B, STOPSTM to reduce HBV S-antigen, and next-generation antisense oligonucleotides (e.g., ALG-020572).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aligos Therapeutics company profile →
Inversago Pharma
HQ: Canada
Website
- Description: Provider of clinical-stage biotech therapies based on peripherally-acting CB1 inverse agonists, including INV-202, a small molecule CB1 receptor blocker for metabolic disorders in Phase 2 studies for diabetic kidney disease and obesity, and INV-347, a next-generation oral CB1 receptor blocker in Phase 1 evaluating safety, tolerability, and pharmacokinetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inversago Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Calliditas Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Calliditas Therapeutics
2.2 - Growth funds investing in similar companies to Calliditas Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Calliditas Therapeutics
4.2 - Public trading comparable groups for Calliditas Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →